Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.46 |
| ▸ | IDH2 | P48735 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127141 | 1.00 | IDH1 (0.46) | IDH1IDH2ADORA2AMAPK8OPRK1 | |
| SCHEMBL31127128 | 0.81 | IDH1 (0.58) | IDH1IDH2OPRK1CCNT1 | |
| SCHEMBL21143768 | 0.81 | IDH1 (0.58) | IDH1IDH2OPRK1CCNT1 | |
| SCHEMBL19687117 | 0.80 | LMNA (0.49) | IDH1IDH2ADORA2ACCNT1MAPT | |
| SCHEMBL19686534 | 0.80 | IDH1 (0.48) | IDH1IDH2OPRK1 | |
| SCHEMBL21144351 | 0.79 | IDH1 (0.47) | IDH1IDH2OPRK1CCNT1 | |
| SCHEMBL31127241 | 0.79 | IDH1 (0.47) | IDH1IDH2OPRK1CCNT1 | |
| SCHEMBL21144155 | 0.78 | IDH1 (0.69) | IDH1 | |
| SCHEMBL19686822 | 0.78 | IDH1 (0.47) | IDH1IDH2OPRK1CCNT1 | |
| SCHEMBL19686558 | 0.78 | IDH1 (0.47) | IDH1IDH2MAPK8OPRK1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885ADORA2A 1711/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885ADORA2A 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.